Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
Phase III Vitiligo Study
The research study is being conducted to look at the efficacy of SCENESSE® (also known as afamelanotide) combined with narrow-band ultraviolet B (NB-UVB) light in participants with nonsegmental vitiligo. Procedures: vital signs, physical examination, medical history, blood and urine tests, past and current medications, full body photography, NB-UVB light treatment, study medication implant administration. subject questionnaires and skin assessments.
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
The purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian cancer risk reduction in women with BRCA1 mutations who have completed childbearing. In this study, the removal of fallopian tubes will be compared to the removal of fallopian tubes and ovaries. The study will also examine what factors go into deciding which surgery to have and symptoms after surgery caused by lack of estrogen due to ovary removal.
IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
The purpose of this study is to study a new radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body to see how it is taken up in the body and the brain using an imaging procedure called Positron Emission Tomography (PET/CT). Imaging PARP-1 activity in various cancers may help researchers to better understand it’s function and determine the best way to use imaging to help study new treatments that target the PARP-1 enzyme.
RevitaT2Di Pivotal Study (REVITALIZE 1)
The Revitalize-1 Study will look at a potential procedure called duodenal mucosal resurfacing (DMR). The DMR procedure acts on the first layer (mucosa) of the duodenum (the part of the small intestine located immediately after the stomach). By removing an excess layer, the treatment may improve blood sugar control. This treatment may eliminate or reduce the need for insulin injections in the future for the treatment of Type 2 Diabetes.
A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose.
ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not in normal tissue.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
